Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | RPTX | Common Shares | Sale | -$10.5M | -303K | -6.57% | $34.80 | 4.3M | May 21, 2021 | See Footnote | F1, F2, F3, F4 |
transaction | RPTX | Common Shares | Sale | -$118K | -3.55K | -0.08% | $33.30 | 4.3M | May 24, 2021 | See Footnote | F1, F5, F6, F7 |
transaction | RPTX | Common Shares | Sale | -$639K | -18.7K | -0.43% | $34.28 | 4.28M | May 24, 2021 | See Footnote | F1, F8, F9, F10 |
Id | Content |
---|---|
F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. |
F2 | The shares were sold as follows: 128,922 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,437 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 169,310 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). |
F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.40 to $34.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F4 | The shares are held as follows: 2,215,139 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 76,247 by AM BV2014 and 1,874,202 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
F5 | The shares were sold as follows: 1,511 by BV 2014, 52 by AM BV2014 and 1,984 by UBS Oncology. |
F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $33.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F7 | The shares are held as follows: 2,213,628 by BV 2014, 135,843 by BV 2014(B), 76,195 by AM BV2014 and 1,872,218 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
F8 | The shares were sold as follows: 7,945 by BV 2014, 274 by AM BV2014 and 10,434 by UBS Oncology. |
F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.60 to $34.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F10 | The shares are held as follows: 2,205,683 by BV 2014, 135,843 by BV 2014(B), 75,921 by AM BV2014 and 1,861,784 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |